What Is the Merck & Co., Inc. (MRK) Class Action Lawsuit About?
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Merck & Co., Inc. (“Merck” or “the Company”) (NYSE: MRK) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Merck securities between February 3, 2022, and February 3, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case.
What Does the Merck & Co., Inc. Securities Class Action Allege?
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) defendants created the false impression that they possessed reliable information pertaining to Merck’s projected revenue outlook and anticipated growth of Gardasil while also minimizing risk from competition and drug approval development, such as China’s approval to shift Gardasil to a 2-dose regimen; (2) in truth, Merck’s optimistic reports of growth, claims of successful consumer activation and education in China, overall ability to drive demand, and efforts to downplay the impact of competition on Gardasil fell short of the reality; and (3) Merck’s ability to push Gardasil in China had materially diminished.
What’s Next?
A class action lawsuit has already been filed. You may review a copy of the Complaint. You may also contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660. If you suffered a loss in Merck you have until April 14, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff.
How Did Merck & Co., Inc. (MRK) Stock React to the Disclosures?
How Is BG&G Representing Investors in Securities Class Actions?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”